Jabbour, E., Sallman, D., Briseno-Toomey, D., Guttke, C. D., Huang, X., Dillon, R., Ferrante, L., Ikezoe, T., Langlois, A., Loefgren, C., Nachmias, B., Nelson, A., Packman, K., Shastri, P. N., Récher, C., Roboz, G., Schuier, N., Thayu, M., Trancucci, D., Zuppa, A., Röllig, C., Wei, A. (2025). Camelot-2: A phase 3 randomized, double-blind, placebo-controlled, study of bleximenib, venetoclax and azacitidine for the treatment of participants with newly diagnosed Acute Myeloid Leukemia harboring KMT2A rearrangements or NPM1 mutations, who are ineligible for intensive chemotherapy. Blood. https://doi.org/10.1182/blood-2025-3429